References
- Jaffe E S, Harris N L, Stein H, Vardiman J W. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. IARC, Lyon 2001
- The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
- Conconi A, Martinelli G, Thieblemont C, Ferreri A J, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741–2745
- Bennett M, Sharma K, Yegena S, Gavish I, Dave H P, Schechter G P. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90: 856–858
- Tsimberidou A M, Catovsky D, Schlette E, O'Brien S, Wierda W G, Kantarjian H, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107: 125–135
- Raderer M, Jäger G, Brugger S, Puspok A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Oncology 2003; 65: 306–310
- Martinelli G, Laszlo D, Ferreri A J, Pruneri G, Ponzoni M, Conconi, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or noteligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979–1983
- Ferreri A J, Ponzoni M, Martinelli G, Muti G, Guidoboni M, Dolcetti R, et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005; 90: 1578–1579
- Ghielmini M, Schmitz S -FH, Cogliatti S B, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004; 103: 4416–4423
- Raderer M, Wohrer S, Streubel B, Drach J, Jager U, Turetschek K, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006; 70: 411–447